Fred E. Cohen - Feb 12, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Director, 10%+ Owner
Signature
By: /s/ Fred E. Cohen
Stock symbol
KYTX
Transactions as of
Feb 12, 2024
Transactions value $
$0
Form type
4
Date filed
2/14/2024, 07:03 PM
Previous filing
Feb 7, 2024
Next filing
May 28, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Conversion of derivative security +4.52M 4.52M Feb 12, 2024 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Series A-1 Redeemable Convertible Preferred Stock Conversion of derivative security $0 -4.4M -100% $0.00* 0 Feb 12, 2024 Common Stock 967K See Footnote F2, F3
transaction KYTX Series A-2 Redeemable Convertible Preferred Stock Conversion of derivative security $0 -8.83M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.94M See Footnote F2, F3
transaction KYTX Series B Redeemable Convertible Preferred Stock Conversion of derivative security $0 -7.36M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.62M See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2 Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.
F3 The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.